University of Turku Reports Findings in Cancer Gene Therapy (Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens)
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Fresh data on Biotechnology are presented in a new report. According to news originating from Turku, Finland, by NewsRx correspondents, research stated, "The benefits of PSA (prostate specific antigen)-testing in prostate cancer remain controversial with a consequential need for validation of additional biomarkers. We used highly standardized reverse-transcription (RT)-PCR assays to compare transcript levels of 10 candidate cancer marker genes -BMP6, FGF-8b, KLK2, KLK3, KLK4, KLK15, MSMB, PCA3, PSCA and Trpm8 -in carefully ascertained non-cancerous versus cancerous prostate tissue from patients with clinically localized prostate cancer treated by radical prostatectomy."
Our news journalists obtained a quote from the research from the University of Turku, "Total RNA was isolated from fresh frozen prostate tissue procured immediately after resection from two separate areas in each of 87 radical prostatectomy specimens. Subsequent histopathological assessment classified 86 samples as cancerous and 88 as histologically benign prostate tissue. Variation in total RNA recovery was accounted for by using external and internal standards and enabled us to measure transcript levels by RT-PCR in a highly quantitative manner. Of the ten genes, there were significantly higher levels only of one of the less abundant transcripts, PCA3, in cancerous versus non-cancerous prostate tissue whereas PSCA mRNA levels were significantly lower in cancerous versus histologically benign tissue. Advanced pathologic stage was associated with significantly higher expression of KLK15 and PCA3 mRNAs. Median transcript levels of the most abundantly expressed genes (i.e. MSMB, KLK3, KLK4 and KLK2) in prostate tissue were up to 10(5)-fold higher than those of other gene targets."
According to the news editors, the research concluded: "PCA3 expression was associated with advanced pathological stage but the magnitude of overexpression of PCA3 in cancerous versus non-cancerous prostate tissue was modest compared to previously reported data."
For more information on this research see: Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens. Clinical Biochemistry, 2013;46(7-8):670-4. (Elsevier - www.elsevier.com; Clinical Biochemistry - www.elsevier.com/wps/product/cws_home/525463)
The news correspondents report that additional information may be obtained from R.M. Vaananen, Division of Biotechnology, University of Turku, Turku, Finland. Additional authors for this research include H. Lilja, A. Cronin, L. Kauko, M. Rissanen, O. Kauko, H. Kekki, S. Vidback, M. Nurmi, K. Alanen and K. Pettersson (see also Biotechnology).
Keywords for this news article include: Biotechnology, Turku, Europe, Finland, Genetics, Oncology, Cancer Gene Therapy.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC